{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:03:06Z","timestamp":1794002586593,"version":"4.8.0"},"reference-count":29,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,2,13]],"date-time":"2006-02-13T00:00:00Z","timestamp":1139788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2006,4]]},"abstract":"<jats:p><jats:bold>BACKGROUND:\u2002<\/jats:bold> In contrast to other extracorporeal treatments no established regime exists for anticoagulation with low\u2010molecular\u2010weight heparin (LMWH) in plasmapheresis therapy. A study was conducted to investigate whether LMWH (dalteparin\u2010Na) is suitable as an effective anticoagulant in plasmapheresis therapy.<\/jats:p><jats:p><jats:bold>STUDY DESIGN AND METHODS:\u2002<\/jats:bold> Eleven patients with autoimmune neurological diseases and the necessity for a plasmapheresis therapy were enrolled. A capillary membrane filter was used. A total of 2000\u2003mL of human plasma was isovolumetrically exchanged per plasmapheresis cycle. The anticoagulation was accomplished with a single bolus of LMWH (dalteparin) of 80 to 90\u2003IU per kg of body weight. The system was visually monitored. Anti\u2010factor (F)Xa activity, thrombin\u2013antithrombin III complex (TAT), and prothrombin fragment 1+2 (F\u20031+2) were determined at regular intervals. Samples were taken from the collected plasma pool to determine the loss of LMWH during the plasmapheresis procedure.<\/jats:p><jats:p><jats:bold>RESULTS:\u2002<\/jats:bold> All plasmapheresis cycles with LMWH were successful without complications. Approximately 40 percent of the initially administered LMWH bolus was lost by the large porous filter during the plasmapheresis. The anti\u2010FXa values were determined to be 0.5\u2003IU per mL during the entire plasmapheresis. TAT values were elevated (TAT median, 14.3\u2003\u00b5g\/L). F\u20031+2 values measured before the filter cartridge remained within the normal range for the entire plasmapheresis cycle (&lt;1.2\u2003nmol\/L) and were increasingly elevated after the filter.<\/jats:p><jats:p><jats:bold>CONCLUSION:\u2002<\/jats:bold> Our initial experiences with LMWH for anticoagulation in plasmapheresis indicate that a body weight adjusted dose of LMWH (dalteparin) is suitable for anticoagulation in plasmapheresis therapy. No complications were observed. The data are encouraging. Further investigations will show if and how the present anticoagulation regime could be further optimized.<\/jats:p>","DOI":"10.1111\/j.1537-2995.2006.00755.x","type":"journal-article","created":{"date-parts":[[2006,2,13]],"date-time":"2006-02-13T09:22:10Z","timestamp":1139822530000},"page":"624-629","source":"Crossref","is-referenced-by-count":15,"title":["Anticoagulation with low\u2010molecular\u2010weight heparin (dalteparin) in plasmapheresis therapy: initial experience"],"prefix":"10.1111","volume":"46","author":[{"given":"Helmut","family":"Schinzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Berghoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Beuermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc\u2010Alexander","family":"Von Mach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig Sacha","family":"Weilemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,2,13]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0749-0704(01)00010-0"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-0968.2003.00004.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-0968.2003.00036.x"},{"key":"e_1_2_6_5_2","first-page":"295","article-title":"Plasmapheresis in neurological diseases: experience in 140 procedures in 47 patients","volume":"123","author":"Nogates\u2010Gaete J","year":"2004","journal-title":"Rev Med Chil"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/286456a0"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1982.22583017463.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/039139888801100416","article-title":"Optimzation of heparin anticoagulation during membrane plasma separation","volume":"11","author":"Frasca GM","year":"1988","journal-title":"J Artif Organs"},{"key":"e_1_2_6_9_2","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1177\/039139888901200811","article-title":"Optimization of heparinization in clinical double filtration plasmapheresis","volume":"12","author":"Hosokawa S","year":"1989","journal-title":"Int J Artif Organs"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/jca.2920050406"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/039139889001301110"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1594.2003.07132.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200006000-00012"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1646768"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1647475"},{"key":"e_1_2_6_16_2","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1182\/blood.V59.5.1086.1086","article-title":"Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2\/F1+2\u2010fragment and thrombin\u2010antithrombin\u2010complex","volume":"59","author":"Teiel JM","year":"1982","journal-title":"Blood"},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1055\/s-0038-1646288","article-title":"Multicentric evaluation of a new assay for prothrombin fragment 1+2 determination","volume":"68","author":"Bruhn HD","year":"1992","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_18_2","first-page":"278","article-title":"A simple chromogenic assay for heparin and heparin\u2010linked anti\u2010F Xa acitivity in plasma","volume":"53","author":"Holmer E","year":"1985","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-0038-1647623","article-title":"An international standard for low molecular weight heparin","volume":"60","author":"Barrowcliffe TW","year":"1988","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_20_2","first-page":"329","article-title":"Preliminary evaluation of repeated use of a low molecular weight heparin in hemodialysis for chronic renal failure","volume":"22","author":"Anastassiades EG","year":"1985","journal-title":"Proc Eur Dial Trans Assoc"},{"key":"e_1_2_6_21_2","first-page":"179","article-title":"Hemodialysis with low molecular weight heparin: dosage requirement for the elimination of extracorporeal fibrin formation","volume":"1","author":"Lane DA","year":"1986","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_6_22_2","first-page":"31","article-title":"A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis","volume":"27","author":"Ljunberg B","year":"1987","journal-title":"Clin Nephrol"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01708410"},{"key":"e_1_2_6_24_2","first-page":"46","article-title":"Clinical application of Fragmin (FR\u2010860) in hemodialysis: multicenter cooperative study in Japan","volume":"16","author":"Suzuki T","year":"1990","journal-title":"Semin Thromb Hemost"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/14.8.1943"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/16.5.987"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1614206"},{"key":"e_1_2_6_28_2","first-page":"799","article-title":"College of American Pathologists Conference XXXI on Laboratory Monitorin of Anticoagulant Therapy: the clinical use and laboratory monitoring of low\u2010molecular\u2010weight heparin, danaparoid, hirudin and related compounds, and argatroban","volume":"122","author":"Laptosa M","year":"1998","journal-title":"Arch Pathol Lab Med"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7933.2004.00647.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.9.2337.2337"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2006.00755.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1537-2995.2006.00755.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T03:16:31Z","timestamp":1697253391000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1537-2995.2006.00755.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,13]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["10.1111\/j.1537-2995.2006.00755.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1537-2995.2006.00755.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2,13]]}}}